Development and validation of competition binding assays for affinity to the extracellular matrix receptors, αvβ3 and αIIbβ3 integrin

Simple item page
dc.contributor.authorSzabo, Aen_AU
dc.contributor.authorHowell, NRen_AU
dc.contributor.authorPellegrini, PAen_AU
dc.contributor.authorGreguric, Ien_AU
dc.contributor.authorKatsifis, Aen_AU
dc.date.accessioned2020-03-23T01:36:26Zen_AU
dc.date.available2020-03-23T01:36:26Zen_AU
dc.date.issued2012-04-01en_AU
dc.date.statistics2020-03-20en_AU
dc.description.abstractThe RGD (Arg-Gly-Asp) binding integrins αvβ3 and αIIbβ3 are integral components of various pathological and physiological processes, including tumor angiogenesis, osteoclast function, and thrombus formation. Because of this, there is interest in identifying novel compounds and proteins binding to these receptors as well as investigating the mechanism of these interactions. In this article, we describe the development and validation of competition binding assays for determining the affinity of test compounds to αvβ3 and αIIbβ3 integrin. Assays were successfully developed for each receptor, and the affinity of known compounds was comparable to published results. However, the inability of binding between αIIbβ3 integrin and the labeled echistatin protein ligand to reach equilibrium resulted in an assay that did not meet the assumptions of the competition binding model. Nevertheless, there was good agreement between this assay and known literature values, and intra- and interassay variability was acceptable. Binding by conformation-specific antibodies provided evidence that solid-phase bound αIIbβ3 receptor was in an activated conformation. This study also demonstrated that current models and methods for determining receptor affinity are simplistic and fail to account for common receptor–ligand interactions such as nondissociable interactions and varying receptor activation states. © 2012 by Elsevier Inc.en_AU
dc.identifier.citationSzabo, A. M., Howell, N. R., Pellegrini, P., Greguric, I., & Katsifis, A. (2012). Development and validation of competition binding assays for affinity to the extracellular matrix receptors, αvβ3 and αIIbβ3 integrin. Analytical Biochemistry, 423(1), 70-77. doi:10.1016/j.ab.2011.12.046en_AU
dc.identifier.govdoc8880en_AU
dc.identifier.issn0003-2697en_AU
dc.identifier.issue1en_AU
dc.identifier.journaltitleAnalytical Biochemistryen_AU
dc.identifier.pagination70-77en_AU
dc.identifier.urihttps://doi.org/10.1016/j.ab.2011.12.046en_AU
dc.identifier.urihttp://apo.ansto.gov.au/dspace/handle/10238/9182en_AU
dc.identifier.volume423en_AU
dc.language.isoenen_AU
dc.publisherElsevier B.V.en_AU
dc.subjectReceptorsen_AU
dc.subjectAffinityen_AU
dc.subjectLigandsen_AU
dc.subjectInteractionsen_AU
dc.subjectTumor cellsen_AU
dc.subjectAngiogenesisen_AU
dc.subjectBone marrow cellsen_AU
dc.titleDevelopment and validation of competition binding assays for affinity to the extracellular matrix receptors, αvβ3 and αIIbβ3 integrinen_AU
dc.typeJournal Articleen_AU
Files
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Journal Articles